Advertisement


Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors

NCCN 2020 Virtual Annual Conference

Advertisement

Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses his study findings, which show that alectinib was associated with longer treatment persistence and comparable adherence to other ALK inhibitors (Abstract HSR20-084).



Related Videos

Breast Cancer

Elizabeth Reed, MD, on Helping Providers in Rural Areas Meet the Needs of Younger Patients With Breast Cancer

Elizabeth Reed, MD, of the University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center, talks about how she and her team sought to help rural oncology provi...

Solid Tumors

Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care

Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced...

Breast Cancer

Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or ...

Issues in Oncology
Symptom Management

Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment

Karen Wonders, PhD, of Wright State University, discusses the safety and efficacy of exercise during cancer treatment in minimizing toxicities and addressing the short- and l...

Issues in Oncology

Barbara DeVivo, PhD, MBA, on Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making

Barbara DeVivo, PhD, MBA, of Westmont College, talks about how the culture and structure of tumor boards—and their invisible status hierarchies—may hamper collaboration and i...

Advertisement

Advertisement



Advertisement